Fonte: Journal of thoracic oncology. Nome do evento: World conference on lun cancer - ASLC. Unidades: FM, FMRP
Assuntos: NEOPLASIAS PULMONARES, ADENOCARCINOMA, PULMÃO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MACHADO, Juliana et al. Clinical relevant oncogenic drivers in advanced adenocarcinoma discloses new therapeutic target in negative EGFR/ALK/KRAS patients. Journal of thoracic oncology. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/12/issue/1/suppl/S. Acesso em: 29 jul. 2024. , 2017APA
Machado, J., Nagai, M. A., Fabro, A. T., & Capelozzi, V. L. (2017). Clinical relevant oncogenic drivers in advanced adenocarcinoma discloses new therapeutic target in negative EGFR/ALK/KRAS patients. Journal of thoracic oncology. New York: Faculdade de Medicina, Universidade de São Paulo. Recuperado de https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/12/issue/1/suppl/SNLM
Machado J, Nagai MA, Fabro AT, Capelozzi VL. Clinical relevant oncogenic drivers in advanced adenocarcinoma discloses new therapeutic target in negative EGFR/ALK/KRAS patients [Internet]. Journal of thoracic oncology. 2017 ; 12( 1): S955.[citado 2024 jul. 29 ] Available from: https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/12/issue/1/suppl/SVancouver
Machado J, Nagai MA, Fabro AT, Capelozzi VL. Clinical relevant oncogenic drivers in advanced adenocarcinoma discloses new therapeutic target in negative EGFR/ALK/KRAS patients [Internet]. Journal of thoracic oncology. 2017 ; 12( 1): S955.[citado 2024 jul. 29 ] Available from: https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/12/issue/1/suppl/S
